Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospecti...
Saved in:
Published in | Biomolecules & Biomedicine Vol. 24; no. 5; pp. 1400 - 1406 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Bosnia and Herzegovina
Association of Basic Medical Sciences
01.10.2024
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management. |
---|---|
AbstractList | Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management. Keywords: Inflammatory bowel disease (IBD), vedolizumab, Crohn's disease (CD), ulcerative colitis (UC), real-world efficacy. Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management. Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved by 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-TNF exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in a real-world setting in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management. Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management.Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across six medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation. At 26 weeks, clinical remission was achieved in 82.9% of UC patients and 85.7% of CD patients. Mucosal healing was observed in 38.1% of CD patients. The efficacy of vedolizumab did not significantly differ based on prior anti-tumor necrosis factor (anti-TNF) exposure. Notably, the clinical scoring tools for predicting vedolizumab response showed limited applicability in this cohort. Vedolizumab demonstrated high efficacy in treating both UC and CD in real-world settings in Bosnia and Herzegovina, underscoring its potential as a significant therapeutic option in IBD management. |
Audience | Academic |
Author | Jovanović, Predrag Babić, Emil Tošić, Zoran Bašić Denjagić, Mirela Salkić, Nermin Saray, Aida Zubčević, Nađa Tamburić, Renata Husić Selimović, Azra Barać, Tatjana Dobrovoljski, Aleksandar Bevanda, Milenko |
AuthorAffiliation | 6 Department of Gastroenterology and Hepatology, University Clinical Hospital of Mostar, Mostar, Bosnia and Herzegovina 7 Department of Gastroenterology, Health Center Brčko, Brčko, Bosnia and Herzegovina 4 Clinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina 2 Department of Gastroenterology and Hepatology, University Clinical Center of Tuzla, Tuzla, Bosnia and Herzegovina 1 Department of Internal Medicine, School of Medicine Tuzla, University of Tuzla, Tuzla, Bosnia and Herzegovina 5 Department of Internal Medicine, General Hospital “Abdulah Nakaš” Sarajevo, Sarajevo, Bosnia and Herzegovina 3 Clinic of Gastroenterohepatology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina |
AuthorAffiliation_xml | – name: 2 Department of Gastroenterology and Hepatology, University Clinical Center of Tuzla, Tuzla, Bosnia and Herzegovina – name: 3 Clinic of Gastroenterohepatology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina – name: 5 Department of Internal Medicine, General Hospital “Abdulah Nakaš” Sarajevo, Sarajevo, Bosnia and Herzegovina – name: 7 Department of Gastroenterology, Health Center Brčko, Brčko, Bosnia and Herzegovina – name: 6 Department of Gastroenterology and Hepatology, University Clinical Hospital of Mostar, Mostar, Bosnia and Herzegovina – name: 4 Clinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina – name: 1 Department of Internal Medicine, School of Medicine Tuzla, University of Tuzla, Tuzla, Bosnia and Herzegovina |
Author_xml | – sequence: 1 givenname: Nermin surname: Salkić fullname: Salkić, Nermin organization: Department of Internal Medicine, School of Medicine Tuzla, University of Tuzla, Tuzla, Bosnia and Herzegovina – sequence: 2 givenname: Mirela surname: Bašić Denjagić fullname: Bašić Denjagić, Mirela organization: Department of Gastroenterology and Hepatology, University Clinical Center of Tuzla, Tuzla, Bosnia and Herzegovina – sequence: 3 givenname: Nađa surname: Zubčević fullname: Zubčević, Nađa organization: Clinic of Gastroenterohepatology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina – sequence: 4 givenname: Renata surname: Tamburić fullname: Tamburić, Renata organization: Clinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina – sequence: 5 givenname: Azra surname: Husić Selimović fullname: Husić Selimović, Azra organization: Department of Internal Medicine, General Hospital "Abdulah Nakaš" Sarajevo, Sarajevo, Bosnia and Herzegovina – sequence: 6 givenname: Emil surname: Babić fullname: Babić, Emil organization: Department of Gastroenterology and Hepatology, University Clinical Hospital of Mostar, Mostar, Bosnia and Herzegovina – sequence: 7 givenname: Milenko surname: Bevanda fullname: Bevanda, Milenko organization: Department of Gastroenterology and Hepatology, University Clinical Hospital of Mostar, Mostar, Bosnia and Herzegovina – sequence: 8 givenname: Aida surname: Saray fullname: Saray, Aida organization: Clinic of Gastroenterohepatology, University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina – sequence: 9 givenname: Predrag surname: Jovanović fullname: Jovanović, Predrag organization: Department of Internal Medicine, School of Medicine Tuzla, University of Tuzla, Tuzla, Bosnia and Herzegovina; Department of Gastroenterology and Hepatology, University Clinical Center of Tuzla, Tuzla, Bosnia and Herzegovina – sequence: 10 givenname: Zoran surname: Tošić fullname: Tošić, Zoran organization: Department of Gastroenterology, Health Center Brčko, Brčko, Bosnia and Herzegovina – sequence: 11 givenname: Aleksandar surname: Dobrovoljski fullname: Dobrovoljski, Aleksandar organization: Clinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina – sequence: 12 givenname: Tatjana surname: Barać fullname: Barać, Tatjana organization: Clinic of Gastroenterology and Hepatology, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38683174$$D View this record in MEDLINE/PubMed |
BookMark | eNptUk1v1DAQjVARLaVXjsgSFy5ZxnES2ydUKqCVKnEAJG6WP8a7rpK42NlW2wO_He9uW1Gp8sHWmzfPb0bvdXUwxQmr6i2FBeUMuo_GLBpo2gWFlrEX1VEjGK1Bwu-Dh7eQ_WF1kvMVADSCN6KHV9UhE32p8vao-vtjFdNcz5hGgt4Hq-2GRE9u0MUh3K1HbUiYyLWeA05zJrdhXhXAD3oc9RzThph4iwNxIaPOuOUm1EM9BI8k4zyHaZm36OeYp6CJnhw5x3SHy3gTJv2meun1kPHk_j6ufn398vPsvL78_u3i7PSyti3IubaeMoPGS7CIwkmmO4Ods54DZbyh3glJgbOGcwOcc-hsD70VrHUURAfsuLrY67qor9R1CqNOGxV1UDsgpqXSaQ52QCVY33vskZXvWtNw03XUecdF6yyg9UXr017rem1GdLbsJenhiejTyhRWqoyraPEqodm6-XCvkOKfNeZZjSFbHAY9YVxnxaAVvBfQtYX6fk9d6uKtLD4WSbulq1MBUjKQrSysxTOschyOwZbQ-FDw5xpsijkn9I_2KahdtpQxapsttctWaXj3_9CP9IcksX-b7Mzf |
ContentType | Journal Article |
Copyright | COPYRIGHT 2024 Association of Basic Medical Sciences 2024 Salkić et al. 2024 |
Copyright_xml | – notice: COPYRIGHT 2024 Association of Basic Medical Sciences – notice: 2024 Salkić et al. 2024 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.17305/bb.2024.10433 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2831-090X |
EndPage | 1406 |
ExternalDocumentID | oai_doaj_org_article_8366fe6e3bf94b27b551dfd784dc0ecf A809930949 10_17305_bb_2024_10433 38683174 |
Genre | Multicenter Study Journal Article Observational Study |
GeographicLocations | Bosnia and Herzegovina |
GeographicLocations_xml | – name: Bosnia and Herzegovina |
GroupedDBID | 53G ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF EBD ECM EIF EMB EMOBN EOJEC GROUPED_DOAJ IAO IHR INH ITC MK0 NPM OBODZ PGMZT PV9 RPM RZL SV3 AAYXX CITATION M~E 7X8 5PM |
ID | FETCH-LOGICAL-c409t-cf13bebf90cee8d93a5be5dcf7013721fd891073277b077705c606c834d108503 |
IEDL.DBID | RPM |
ISSN | 2831-0896 2831-090X |
IngestDate | Thu Jul 04 21:04:47 EDT 2024 Wed Oct 02 05:41:54 EDT 2024 Tue Oct 01 16:30:53 EDT 2024 Wed Oct 02 17:18:13 EDT 2024 Tue Oct 01 04:01:34 EDT 2024 Thu Sep 26 20:25:18 EDT 2024 Wed Oct 02 05:22:41 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c409t-cf13bebf90cee8d93a5be5dcf7013721fd891073277b077705c606c834d108503 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-7271-4980 0000-0003-0229-6688 0000-0001-5547-5159 0000-0003-4727-9267 0009-0008-0009-1279 0000-0001-9485-4901 0009-0007-8362-3850 0000-0002-5436-2424 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379020/ |
PMID | 38683174 |
PQID | 3048768054 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8366fe6e3bf94b27b551dfd784dc0ecf pubmedcentral_primary_oai_pubmedcentral_nih_gov_11379020 proquest_miscellaneous_3048768054 gale_infotracmisc_A809930949 gale_infotracacademiconefile_A809930949 crossref_primary_10_17305_bb_2024_10433 pubmed_primary_38683174 |
PublicationCentury | 2000 |
PublicationDate | 20241001 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: 20241001 day: 1 |
PublicationDecade | 2020 |
PublicationPlace | Bosnia and Herzegovina |
PublicationPlace_xml | – name: Bosnia and Herzegovina |
PublicationTitle | Biomolecules & Biomedicine |
PublicationTitleAlternate | Biomol Biomed |
PublicationYear | 2024 |
Publisher | Association of Basic Medical Sciences Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
Publisher_xml | – name: Association of Basic Medical Sciences – name: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
SSID | ssj0002872860 ssib054421647 |
Score | 2.3118587 |
Snippet | Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims... Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1400 |
SubjectTerms | Adult Analysis Antibodies, Monoclonal, Humanized - therapeutic use Bosnia and Herzegovina Care and treatment Colitis, Ulcerative - drug therapy Composition Crohn Disease - drug therapy Crohn's disease (CD) Diagnosis Female Gastrointestinal Agents - therapeutic use Humans Immune response Inflammatory bowel disease (IBD) Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Male Microbiota (Symbiotic organisms) Middle Aged real-world efficacy Retrospective Studies Treatment Outcome ulcerative colitis (UC) vedolizumab |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp1xKS1_bpkWBQk8mtmVZ8jEpDUsgvbSB3IRGj8ZlY5d4N6U55LdnRnaWNT300qsksDzzSfPQ6BNjH13UuQWZZ8EXkFWUaLJ5EBlE11TWRadSEc3513p5UZ1dysudp76oJmykBx4Fd6RFXcdQBwGxqaBUgCbeR6905V0eXEy7byF3gilEkqyqckuU9TOlkFSp05VhNKeUE2zqicERES6PADBSLCs68BRiZqESkf_f2_WOvZrXUu4Yp9Nn7OnkVfLj8W-esyehe8Huv12hb53R3ssDMUVY94f3kd8G36_au821Bd52fGJWHTilZLEhIkau09k7h_53WPHpDIfGooe5ylZtDHwIqWB6oNaTfuhay23n-TLc3IUflKWwL9nF6Zfvn5fZ9NxC5jDIW2cuFgICijlHw6l9I6yEIL2LimgJyyJ6jb6FEqVSkCulcukw-nFaVJ6uMOTiFdvr-i68YTwvvKeHlRpBDIMQGu2hlFbJWtQKCrVgnx5FbH6NrBqGohFShgEwpAyTlLFgJ6SB7Shiw04NiBEzYcT8CyP4OdKfoTWLSkJxj1cPcLLEfmWONfrJAgPdZsEOZiNxrblZ9-EjAgx1UYFaF_rNYATuhBi5IfIW7PWIiO2cha4RdAp79Awrs5-a93TtVaL6LlDyDXr0b_-HGN6xfRLsWIp4wPbWN5vwHl2qNXxIq-cBBhgeMg priority: 102 providerName: Directory of Open Access Journals |
Title | Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38683174 https://www.proquest.com/docview/3048768054/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC11379020 https://doaj.org/article/8366fe6e3bf94b27b551dfd784dc0ecf |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJTr2Ulr7cPFCh0JOztmVb8jEJCUthS6EN5Cb0TFx27bDebWkO-e2Zke0lprdefJBkLGs-aR4afSLks_EiUbpIYmdTHecYaFKJY7H2psqV8YaHJJrFt3J-nX-9KW72SDmehQlJ-0bXp81yddrUdyG38n5lZmOe2Oz74iJNGa_Azpntk33O2NRHL_I825Fk_QrhI56JcFwYVCnGA6tyYG8EdBczrcFLzHLc7GR4qw4TJTTj-URRBT7_f1ftZ2prmlL5TEddvSIvB-OSnvU_8ZrsueYNefxxByZ2jEswdUgYocxf2nr629l2WT9sV0rTuqEDwWpHMTILBR6gsgpb8FS3f9ySDls52BYMzWW8rL2jnQt50x2WnrddUyuqGkvnbv3gbjFYod6S66vLnxfzeLh1ITbg621i41OmnfZVAvpT2IqpQrvCGs-RnTBLvRVgYnCWca4TznlSGHCCjGC5xZMMCXtHDpq2cR8ITVJr8X6liiHRoHaVsDorFC9KVnKd8oh8GYdY3vfkGhKdEpSL1FqiXGSQS0TOUQK7VkiKHQra9a0coCEFK0vvSseg87nOuAZr0HrLRW5N4oyHz6H8JE5dEBIMd38CATqLJFjyTIC5zMDfrSJyNGkJU85Mqj-NCJBYhXlqjWu3nWSwIIIDByCMyPseEbs-j8CKiJhgZfJT0xqYAIHxewT8x_9_9ZC8wOHs8xCPyMFmvXXHYE9t9EmIQ8Bz8Xh5EqbSE6nVH80 |
link.rule.ids | 230,315,733,786,790,870,891,2115,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLZKOcCFRSwNFDASEqfMJHESO8e2ohqgUyHRit6seGsDM0k1C4g58Nt5z0lGDZzgajuK7ffZb_HzZ0LeaCeiUmVRaE2swhQDTWVkWaicLtJSO819Es30NJ-cpx8usosdkvd3YXzSvlbVqJ7NR3V15XMrr-d63OeJjT9Nj-KY8QLsnPEtchsWbMKHXnqWpsmWJuurDyDxRPgLw6BMMSJY5B1_I-A7GysFfmKS4nEnw3d1mMihGU8Hqsoz-v-9b99QXMOkyhta6vg--dKPr01O-TZar9RIb_6gfvz3CXhA7nWGKz1o6x-SHVs_Ir8-X4H5HuL2Ti2SUZT6J20c_W5NM6s263mpaFXTjrx1STHqCwUOYDj3x_tUNT_sjHbHRNgWjNhZOKucpUvrc7KXWHrYLOuqpGVt6MQuNvYSAyHlY3J-_O7saBJ2LzqEGvzIVahdzJRVrohANwtTsDJTNjPacWQ-TGJnBJgvnCWcq4hzHmUaHCwtWGrwlkTEnpDduqntHqFRbAy-3VQwJDFUthBGJVnJs5zlXMU8IG974cnrlrhDosODEpdKSZS49BIPyCHKdtsKCbd9QbO4lN2sS8Hy3NncMuh8qhKuwNI0znCRGh1Z7eB3iAyJ2wKIH6a7vd0AnUWCLXkgwBRn4EsXAdkftITlrAfVr3tsSazCHLjaNuulZLDZgnMI8A7I0xZr2z73kA2IGKBwMKhhDWDLs4n3WHr2_5--IncmZ9MTefL-9ONzchents133Ce7q8XavgC7baVe-kX6GwR9P8c |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgSIgXLuJWGGAkJJ7SJnESO4_boCqXTZNg0iQerPi2BdqkaloQfeC3c46TVAu87dU-VR2fzz4XH38m5I12IixUGgbWRCpIMNFUhJYFyuk8KbTT3BfRHJ9ks7Pk43l63lVVNl1ZZaVVOa7mi3FVXvrayuVCT_o6scnp8VEUMZ6DnzNZGje5SW7Boo3zYaSeJkm8o8r67pNIPBb-0jAYVMwK5lnH4QgYTydKQawYJ3jkyfBtHSYyEOPJwFx5Vv__9-4rxmtYWHnFUk3vkW_9N7YFKj_Gm7Ua6-0_9I_Xm4T75G7nwNKDVuYBuWGrh-TPl0tw4wPc5qlFUopC_6a1oz-tqefldrMoFC0r2pG4NhSzv9DgAI4Lf8xPVf3Lzml3XISy4MzOg3npLG2sr81usPWwbqqyoEVl6MyutvYCEyLFI3I2ff_1aBZ0LzsEGuLJdaBdxJRVLg_BRguTsyJVNjXacWRAjCNnBLgxnMWcq5BzHqYaAi0tWGLwtkTIHpO9qq7sU0LDyBh8wylnSGaobC6MitOCpxnLuIr4iLztFSiXLYGHxMAHtS6Vkqh16bU-Ioeo350UEm_7hnp1IbuZl4JlmbOZZTD4RMVcgcdpnOEiMTq02sHfITokbg8AAZju9pYDDBaJtuSBAJecQUydj8j-QBKWtR50v-7xJbELa-EqW28ayWDThSARID4iT1q87cbcw3ZExACJg48a9gC-PKt4j6dn1__pK3L79N1Ufv5w8uk5uYMz25Y97pO99WpjX4D7tlYv_Tr9C_w5Qkc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short-term+efficacy+of+vedolizumab+in+patients+with+inflammatory+bowel+disease+in+real-life+settings+in+Bosnia+and+Herzegovina&rft.jtitle=Biomolecules+%26+biomedicine&rft.au=Salki%C4%87%2C+Nermin&rft.au=Ba%C5%A1i%C4%87+Denjagi%C4%87%2C+Mirela&rft.au=Zub%C4%8Devi%C4%87%2C+Na%C4%91a&rft.au=Tamburi%C4%87%2C+Renata&rft.date=2024-10-01&rft.issn=2831-0896&rft.eissn=2831-090X&rft.volume=24&rft.issue=5&rft.spage=1400&rft.epage=1406&rft_id=info:doi/10.17305%2Fbb.2024.10433&rft.externalDBID=n%2Fa&rft.externalDocID=10_17305_bb_2024_10433 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2831-0896&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2831-0896&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2831-0896&client=summon |